Dewpoint’s big year ends with a bang and even bigger hopes for 2025

The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need.

However, not until the last quarter of the year has it become evident just how much the company has achieved. As many as four major announcements in the past three months have made Dewpoint’s progress public.

First came news of a heart disease licensing deal with German life sciences major Bayer (BAYN: DE). This is the first option exercise under the research collaboration between the companies, which began in November 2019, and follows on from Dewpoint’s previously-announced deals with Novo Nordisk (NOV: N) and Merck & Co (NYSE: MRK).